NASDAQ:NKTR

Nektar Therapeutics Stock News

*Your capital is at risk

$72.76

+2.17 (+3.07%)

At Close: Aug 04, 2026

Mizuho Securities Keeps a Buy Rating on uniQure (QURE)

01:15pm, Thursday, 26'th Mar 2020

Mizuho Securities analyst Difei Yang maintained a Buy rating on uniQure (QURE – Research Report) today and set a price

featured in The Global Fintech Index 2020 as the top Fintech company of the country.